I85PREP
⌘ K
CCRA study materials
CCRA study resources

CCRA practice questions

One question at a time. Build your CCRA understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Clinical Research Associate Practice

During a monitoring visit, the CRA discovers that the investigator has been enrolling participants before obtaining written informed consent and documenting it later. Which action best reflects the CRA's responsibility under ICH-GCP E6?

  1. Report the deviation to the sponsor, document it in the monitoring report, and ensure corrective and preventive actions are implemented at the site Correct answer.
  2. Delay reporting the finding until the next scheduled monitoring visit to confirm whether the pattern continues
  3. Reconstruct the consent forms with the participants so the documentation appears compliant before the next monitoring visit
  4. Instruct the site to exclude the affected participants from the study without notifying the sponsor or IRB

Explanation

ICH-GCP E6 requires that informed consent be obtained before any study-related procedure, and the CRA must identify, document, and escalate deviations to the sponsor while ensuring corrective and preventive actions are agreed with the site. Reconstructing documents or concealing findings would constitute falsification and must never be done. Excluding participants without notification would bypass sponsor and IRB oversight of a serious GCP breach.

Question 2Clinical Research Associate Practice

Which document serves as the primary source for verifying that a trial is being conducted according to the protocol, GCP, and applicable regulations during a routine monitoring visit?

  1. The investigator's brochure
  2. The statistical analysis plan
  3. The clinical study report
  4. The source documents and case report forms Correct answer.

Explanation

Source documents are the original records from which CRF data are derived, and source data verification against the CRF is the core of on-site monitoring. The investigator's brochure summarizes preclinical and clinical information about the investigational product but does not record participant-level conduct. The statistical analysis plan and clinical study report are analysis and reporting documents, not sources of participant-level verification.

Question 3Clinical Research Associate Practice

A sponsor asks a CRA to monitor a site where the study coordinator is also the sub-investigator responsible for assessing adverse events. What is the most appropriate CRA response?

  1. Accept the arrangement because the coordinator holds a clinical role
  2. Request that the sponsor waive monitoring at that site
  3. Document the dual role and assess whether it creates a conflict affecting data integrity or participant safety Correct answer.
  4. Report the coordinator to the regulatory authority immediately

Explanation

Delegation of duties must be documented on the delegation log, and the CRA should evaluate whether combined roles compromise data integrity or participant safety. Dual roles are not automatically prohibited, but they must be assessed and documented. Immediate regulatory reporting is not warranted absent an actual violation, and waiving monitoring would remove necessary oversight.

Question 4Clinical Research Associate Practice

Which element must appear on the informed consent form for a trial involving a placebo-controlled design?

  1. The sponsor's internal budget for the trial
  2. The names of all site staff who will interact with the participant
  3. A statement that the participant will definitely receive active treatment
  4. A description of the possible assignment to placebo and the consequences of that assignment Correct answer.

Explanation

ICH-GCP requires that consent information explain the trial design, including the possibility of placebo assignment and its implications for the participant. Claiming guaranteed active treatment would be misleading and invalidate consent. Sponsor budgets and full staff rosters are not required consent elements.

Question 5Clinical Research Associate Practice

During source data verification, a CRA finds that a participant's blood pressure recorded in the CRF as 120/80 does not match the source record of 140/90. What is the correct first step?

  1. Raise a query to the site for resolution and retain an audit trail of the correction Correct answer.
  2. Correct the CRF directly to match the source and initial the change
  3. Ignore the discrepancy because it is not clinically significant
  4. Delete the discrepant CRF entry and re-enter the source value without documentation

Explanation

Data discrepancies must be resolved through the query process, with the site making and documenting corrections so an audit trail is preserved. The CRA should not alter CRF data directly, since the investigator owns the data. Silent deletion or ignoring discrepancies undermines data integrity and traceability.

Question 6Clinical Research Associate Practice

Which situation most clearly requires expedited reporting to the sponsor and possibly the regulatory authority as a serious adverse event?

  1. A participant reports mild headache that resolves with paracetamol
  2. A participant misses a scheduled follow-up visit
  3. A participant is hospitalized for a newly diagnosed arrhythmia during the trial Correct answer.
  4. A participant's laboratory value is slightly outside the reference range with no clinical symptoms

Explanation

A serious adverse event is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization, causes disability, or is a congenital anomaly. Hospitalization for a new arrhythmia meets the seriousness criterion and requires prompt reporting. Mild headache, a missed visit, and asymptomatic borderline labs do not meet seriousness criteria.

Question 7Clinical Research Associate Practice

A CRA reviewing the site's delegation log notices that a study procedure was performed by a staff member not listed on the log. What is the most appropriate action?

  1. Document the finding and require the site to assess the impact and implement corrective action Correct answer.
  2. Take no action because the procedure was completed correctly
  3. Remove the procedure from the participant's record
  4. Retroactively add the staff member to the log with the original date

Explanation

Only staff listed and qualified on the delegation log may perform study procedures, so an unlisted performer is a deviation requiring documentation, impact assessment, and corrective action. Backdating the log would be falsification. Removing records or ignoring the finding would conceal the deviation.

Question 8Clinical Research Associate Practice

Which of the following best describes the purpose of a monitoring plan in a clinical trial?

  1. To define the scope, methods, and frequency of monitoring activities tailored to trial risks Correct answer.
  2. To serve as the statistical analysis strategy for the trial
  3. To replace the need for on-site monitoring entirely
  4. To document the informed consent process for each participant

Explanation

A monitoring plan describes how monitoring will be conducted, including methods, frequency, and the data to be reviewed, and increasingly reflects a risk-based approach. It does not eliminate on-site monitoring or substitute for statistical analysis planning. Participant consent documentation belongs in site records, not the monitoring plan.

Question 9Clinical Research Associate Practice

During a site visit, the CRA learns that the investigator has not reported a serious adverse event to the IRB within the timeframe required by local regulations. What should the CRA do?

  1. Report the omission to the sponsor and ensure the site notifies the IRB promptly with documentation Correct answer.
  2. Quietly submit the IRB report on the investigator's behalf
  3. Advise the site to withdraw the participant from the study
  4. Wait for the next scheduled IRB continuing review to mention it

Explanation

The investigator is responsible for reporting serious adverse events to the IRB within required timelines, and the CRA must identify and escalate failures to the sponsor while ensuring the site corrects the omission. The CRA should not submit IRB reports in place of the investigator. Waiting for continuing review would compound the delay, and withdrawal of the participant is not the remedy for a reporting failure.

Question 10Clinical Research Associate Practice

Which principle of ICH-GCP E6 addresses the requirement that the rights, safety, and well-being of trial participants prevail over the interests of science and society?

  1. Principle 4
  2. Principle 2 Correct answer.
  3. Principle 6
  4. Principle 1

Explanation

ICH-GCP E6 Principle 2 states that the rights, safety, and well-being of trial participants take precedence over the interests of science and society. Principle 1 addresses consistency with the Declaration of Helsinki and applicable regulations. Principle 4 concerns the availability of nonclinical and clinical information adequate to support the trial, and Principle 6 concerns the qualifications of the investigator.

Question 11Clinical Research Associate Practice

A CRA is reviewing a site's investigational product accountability records and finds that dispensing records do not reconcile with returned product. What is the most appropriate interpretation?

  1. This is acceptable because the product is not a controlled substance
  2. This is acceptable if the pharmacy maintains its own separate records
  3. This indicates a potential accountability deviation requiring investigation and documentation Correct answer.
  4. This is expected because returned product is not tracked

Explanation

The investigator must maintain records of investigational product delivery, inventory, dispensing, and return or destruction, and these records must reconcile. An unreconciled discrepancy is a potential deviation that must be investigated and documented. Returned product must be tracked, and controlled-substance status does not change the requirement.

Question 12Clinical Research Associate Practice

Which of the following is the most appropriate way for a CRA to document findings and actions from a monitoring visit?

  1. A note in the participant's medical chart
  2. A verbal briefing to the coordinator with no written record
  3. A written monitoring report submitted to the sponsor within the timeframe specified by the sponsor's procedures Correct answer.
  4. An email to the site investigator only

Explanation

Monitoring findings and actions must be documented in a written monitoring report and submitted to the sponsor within the timeframe specified in the sponsor's procedures. Verbal briefings, participant charts, and isolated emails do not provide the required formal documentation trail.

Question 13Clinical Research Associate Practice

A CRA is asked to monitor a site that is enrolling a vulnerable population, including participants with cognitive impairment. Which consideration is most important?

  1. Requiring that all participants be enrolled by the principal investigator only
  2. Ensuring the consent process includes appropriate safeguards such as legally authorized representatives and independent oversight Correct answer.
  3. Ensuring that the site enrolls a minimum number of participants per month
  4. Confirming that all participants can read and write

Explanation

When participants have impaired capacity to consent, ICH-GCP requires additional safeguards, such as consent from a legally authorized representative and attention to the participant's assent where appropriate. Literacy, who performs enrollment, and enrollment rates are not the central protections for vulnerable populations.

Question 14Clinical Research Associate Practice

Which of the following best describes the CRA's role in ensuring protocol compliance during a monitoring visit?

  1. To approve protocol amendments on behalf of the sponsor
  2. To rewrite the protocol to match site practices
  3. To verify that the site is following the approved protocol and to identify and document deviations Correct answer.
  4. To enroll participants at the site when enrollment is slow

Explanation

The CRA verifies that the site follows the approved protocol and documents any deviations for sponsor review and corrective action. The CRA does not rewrite the protocol, approve amendments, or enroll participants, as these activities fall outside the monitoring role.

Question 15Clinical Research Associate Practice

During a monitoring visit, the CRA notices that the site's temperature logs for investigational product storage are missing for several days. What is the most appropriate action?

  1. Discard the affected product without documentation
  2. Ask the coordinator to recreate the missing temperature logs from memory
  3. Assume the product remained stable and note nothing
  4. Document the gap, assess potential product impact, and escalate to the sponsor for a stability assessment Correct answer.

Explanation

Missing temperature records represent a potential product integrity issue that must be documented, assessed, and escalated to the sponsor, who can evaluate stability and determine whether affected product may be used. Assuming stability, discarding product without documentation, or reconstructing logs from memory would compromise data integrity and participant safety.

Question 16Clinical Research Associate Practice

Which of the following is a key element of the investigator's brochure?

  1. The participant's informed consent form
  2. A summary of nonclinical and clinical information relevant to the investigational product Correct answer.
  3. The site's delegation log
  4. The statistical analysis plan for the current trial

Explanation

The investigator's brochure summarizes nonclinical and clinical information about the investigational product so the investigator can understand its properties and justify the trial. The statistical analysis plan, delegation log, and consent forms are separate trial documents.

Question 17Clinical Research Associate Practice

A CRA finds that a site has enrolled participants who do not meet an inclusion criterion. Which action is most consistent with GCP?

  1. Ask the site to change the inclusion criterion in the protocol
  2. Ignore the issue because the participants are already enrolled
  3. Document the deviation, notify the sponsor, and assess whether the participants' safety or data integrity is affected Correct answer.
  4. Remove the participants' data from the database without documentation

Explanation

Enrolling participants who do not meet eligibility criteria is a protocol deviation that must be documented and reported to the sponsor, with an assessment of safety and data impact. Ignoring the issue, silently removing data, or altering the protocol without formal amendment would violate GCP.

Question 18Clinical Research Associate Practice

Which of the following best describes the concept of risk-based monitoring?

  1. Monitoring is limited to financial auditing of the site
  2. Monitoring is eliminated for all sites
  3. Monitoring is performed only by the sponsor's statisticians
  4. Monitoring activities are prioritized and tailored according to identified risks to participant safety and data integrity Correct answer.

Explanation

Risk-based monitoring directs monitoring resources toward the sites and data most critical to participant safety and data integrity. It does not eliminate monitoring, nor is it conducted by statisticians or limited to financial auditing.

Question 19Clinical Research Associate Practice

A CRA is reviewing a site's essential documents and finds that the IRB approval has expired while enrollment continued. What is the most appropriate action?

  1. Ask the site to submit the approval retroactively to cover the enrollment period
  2. Take no action because the IRB approval was previously valid
  3. Report the finding to the sponsor and ensure enrollment is halted until valid IRB approval is confirmed Correct answer.
  4. Allow enrollment to continue because the site is well established

Explanation

Continued enrollment after IRB approval expires is a serious compliance breach that must be reported to the sponsor, and enrollment should stop until valid approval is confirmed. Retroactive approval cannot legitimize enrollment conducted without valid approval.

Question 20Clinical Research Associate Practice

Which of the following is the CRA's responsibility regarding the site's training records?

  1. Conduct all site staff training personally
  2. Assume staff are trained because they are experienced
  3. Verify that site staff are trained on the protocol and GCP and that training is documented Correct answer.
  4. Store the training records at the sponsor's office only

Explanation

The CRA verifies that site staff have documented training on the protocol, GCP, and relevant procedures. The CRA is not required to personally conduct all training, and training cannot be assumed from experience or stored only off-site without site access.

Question 21Clinical Research Associate Practice

A CRA identifies that a site has not documented a protocol-required procedure in the source record, although the CRF indicates it was performed. What is the most appropriate action?

  1. Delete the CRF entry
  2. Change the CRF to indicate the procedure was not performed
  3. Accept the CRF entry because the procedure was likely done
  4. Query the site to reconcile the CRF with the source and document the resolution Correct answer.

Explanation

If source documentation is absent, the CRA must query the site to reconcile the discrepancy and document how it was resolved. Accepting unverified entries or altering data without site input compromises data integrity and traceability.

Question 22Clinical Research Associate Practice

Which of the following is an essential document that must be maintained at the site and available for monitoring?

  1. The signed investigator agreement and curriculum vitae Correct answer.
  2. The sponsor's internal marketing plan
  3. The site's unrelated financial records
  4. The CRA's personal performance review

Explanation

Essential documents include the signed investigator agreement, curriculum vitae, and other records demonstrating the investigator's qualifications and commitment. Marketing plans, CRA performance reviews, and unrelated financial records are not essential trial documents.

Question 23Clinical Research Associate Practice

A CRA is assessing whether a reported adverse event should be classified as unexpected. Which source should be used to make that determination?

  1. The monitoring plan
  2. The site's delegation log
  3. The investigator's brochure or current reference safety information Correct answer.
  4. The statistical analysis plan

Explanation

An adverse event is unexpected if its nature or severity is not consistent with the applicable reference safety information, typically the investigator's brochure or product labeling. The delegation log, monitoring plan, and statistical analysis plan do not define expectedness.

Question 24Clinical Research Associate Practice

A CRA finds that a site has modified the protocol without sponsor approval to accommodate a scheduling issue. What is the most appropriate action?

  1. Accept the change because it improves efficiency
  2. Make the same change at other sites for consistency
  3. Document the unauthorized protocol modification, report it to the sponsor, and ensure the site reverts to the approved protocol Correct answer.
  4. Ask the site to submit the change for retroactive approval

Explanation

Protocol modifications require sponsor approval and, where applicable, IRB approval before implementation, except where necessary to eliminate an immediate hazard to participants. An unauthorized modification must be documented, reported, and corrected. Retroactive approval or replication at other sites would compound the noncompliance.

Question 25Clinical Research Associate Practice

Which of the following best describes the CRA's role in the close-out of a clinical trial site?

  1. Enrolling the final participants for the site
  2. Writing the clinical study report
  3. Ensuring all essential documents are complete, investigational product is accounted for, and outstanding queries are resolved Correct answer.
  4. Approving the statistical analysis plan

Explanation

At close-out, the CRA verifies that essential documents are complete, investigational product is reconciled, and all queries and outstanding issues are resolved. Enrollment, report writing, and analysis plan approval are not close-out monitoring responsibilities.

Question 26Clinical Research Associate Practice

A CRA is preparing for an initial site qualification visit. Which activity is most appropriate at this stage of site selection?

  1. Verifying that every enrolled participant has signed the current informed consent form
  2. Assessing the site's facilities, staff qualifications, and potential to enroll the target population Correct answer.
  3. Reviewing completed case report forms for consistency with source documents
  4. Reconciling the investigational product accountability records against the dispensing log

Explanation

A qualification visit occurs before enrollment begins, so its purpose is to evaluate whether the site has adequate facilities, trained staff, and access to the target population. Activities such as consent verification and source data review occur once participants are enrolled, during routine monitoring.

Question 27Clinical Research Associate Practice

During a monitoring visit, a CRA discovers that the site's IRB approval letter lists a protocol version older than the one currently in use. What is the most appropriate first action?

  1. Amend the approval letter on the site's behalf to reflect the current protocol version
  2. Instruct the site to stop all study activities immediately and withdraw participants
  3. Ignore the discrepancy because the IRB approval covers the study as a whole
  4. Document the finding, notify the sponsor, and ask the site to obtain IRB approval for the current version Correct answer.

Explanation

Using a protocol version not approved by the IRB is a significant deviation that must be documented and escalated to the sponsor while the site seeks approval for the correct version. The CRA cannot alter regulatory documents, and halting all activities is disproportionate unless participant safety requires it.

Question 28Clinical Research Associate Practice

A CRA is reviewing a site's investigational product storage area and finds that the ambient temperature is recorded once weekly although the pharmacy manual requires daily recording. Which classification best fits this finding?

  1. An unavoidable event outside the site's control requiring no action
  2. A serious breach requiring immediate participant withdrawal
  3. A protocol deviation related to product handling that requires documentation and corrective action Correct answer.
  4. A minor administrative error that can be corrected without documentation

Explanation

Failure to follow the required temperature monitoring schedule is a deviation from the pharmacy manual and protocol handling requirements, so it must be documented and corrected. It does not by itself justify withdrawing participants, and all deviations require a record.

Question 29Clinical Research Associate Practice

Which document typically defines the format and content of the case report form and the source documents the site will use for a specific trial?

  1. The clinical trial protocol and its associated CRF completion guidelines Correct answer.
  2. The site's standard operating procedures for billing
  3. The investigator's brochure
  4. The monitoring plan

Explanation

The protocol, together with CRF completion guidelines, specifies what data are collected and how, and it directs what source documentation is needed. The investigator's brochure summarizes product information, and the monitoring plan describes oversight activities rather than data capture design.

Question 30Clinical Research Associate Practice

A CRA notices that source documents at a site contain handwritten corrections without initials, dates, or reasons. What is the most appropriate response?

  1. Report the site immediately to the regulatory authority for fraud
  2. Accept the corrections because the original values remain legible
  3. Instruct the site to apply proper corrections with initials, date, and reason, and document the finding Correct answer.
  4. Ask the site to retype the affected pages to produce clean records

Explanation

ALCOA principles require corrections to source data to be attributable, dated, and explained while preserving the original entry. The CRA should have the site remediate the records and record the finding in the monitoring report rather than escalate to fraud.

Question 31Clinical Research Associate Practice

Which action best reflects the CRA's responsibility when a site reports that a participant was enrolled despite a prohibited concomitant medication listed in the protocol?

  1. Decide unilaterally whether the participant should continue in the trial
  2. Advise the site to remove the medication from the participant's chart
  3. Take no action because concomitant medication use is the site's clinical judgment
  4. Assess the impact with the site, ensure the event is documented as a deviation, and notify the sponsor Correct answer.

Explanation

Prohibited concomitant medication use constitutes a protocol deviation that must be documented, assessed for participant impact, and communicated to the sponsor. The CRA does not make clinical decisions about participant continuation or alter the medical record.

Question 32Clinical Research Associate Practice

A CRA is verifying informed consent documents and finds that one participant signed the consent form on the same day as, but after, a screening blood draw required only by the study. What is the most appropriate conclusion?

  1. A consent-related deviation occurred because study procedures preceded documented consent Correct answer.
  2. No issue exists because consent was obtained on the same calendar day
  3. The blood draw is exempt because it is a routine screening test
  4. The participant must be withdrawn from the trial automatically

Explanation

Informed consent must be obtained before any study-specific procedure begins, so a study-required blood draw performed before consent is a deviation even if it occurred on the same day. Same-day timing does not cure the sequence problem, and withdrawal is a decision for the investigator and sponsor.

Question 33Clinical Research Associate Practice

Which of the following best describes the purpose of a site initiation visit?

  1. To reconcile the final drug accountability records before archival
  2. To train site staff on the protocol and confirm the site is ready to begin enrollment Correct answer.
  3. To verify the completeness of the trial master file at study end
  4. To audit the site's financial disclosures after study completion

Explanation

A site initiation visit occurs before the site starts enrolling and focuses on training staff, reviewing the protocol and obligations, and confirming readiness. Final reconciliation, financial auditing, and trial master file verification occur later in the study lifecycle.

Question 34Clinical Research Associate Practice

A CRA reviewing a site's delegation log sees that the log was updated to add a new sub-investigator, but no documentation of protocol training for that person exists. What is the most appropriate action?

  1. Assume training occurred because the investigator signed the log
  2. Request documented training before the sub-investigator performs any delegated task, and record the gap Correct answer.
  3. Allow the sub-investigator to continue because the delegation log entry is sufficient
  4. Remove the sub-investigator from the delegation log without informing the site

Explanation

Staff must be trained on the protocol and their delegated duties before performing study tasks, and the delegation log alone does not evidence training. The CRA should obtain documentation and record the deficiency rather than alter site records.

Question 35Clinical Research Associate Practice

Which statement best characterizes the CRA's role regarding the site's adverse event reporting to the sponsor?

  1. The CRA should report adverse events directly to the sponsor on the site's behalf
  2. The CRA verifies that the site has reported adverse events within required timelines and follows up on gaps Correct answer.
  3. The CRA decides which adverse events meet the criteria for seriousness
  4. The CRA determines the causality of each adverse event for the site

Explanation

The investigator is responsible for assessing and reporting adverse events, while the CRA verifies that reporting occurred within required timelines and follows up on deficiencies. Causality and seriousness assessments are the investigator's clinical responsibility.

Question 36Clinical Research Associate Practice

A CRA is planning a monitoring visit and wants to focus effort on the site's highest-risk activities. Which approach is most consistent with a risk-based monitoring strategy?

  1. Reviewing every data field for every participant at every visit regardless of risk
  2. Reviewing only the site's financial records because they carry the greatest regulatory risk
  3. Prioritizing on-site review of critical data and processes identified through centralized and statistical signal detection Correct answer.
  4. Eliminating on-site visits entirely in favor of telephone contact

Explanation

Risk-based monitoring directs monitoring resources toward the data and processes most critical to participant safety and data integrity, informed by centralized and statistical assessments. It does not require 100 percent source data verification or eliminate on-site oversight.

Question 37Clinical Research Associate Practice

During a visit, a CRA finds that the site's essential document file lacks the current signed and dated investigator CV. What is the most appropriate follow-up?

  1. Wait until study close-out to request the document
  2. Note that a CV is optional documentation for sites conducting trials
  3. Request the current signed and dated CV and document the deficiency in the visit report Correct answer.
  4. Photocopy a CV from another investigator at the same institution

Explanation

A current, signed, and dated CV is a required essential document demonstrating the investigator's qualifications, so the CRA should obtain it promptly and record the deficiency. Substituting another person's CV or deferring collection is not acceptable.

Question 38Clinical Research Associate Practice

A CRA observes that a site has been storing unused investigational product in an unlocked cabinet accessible to general clinic staff. Which response best addresses this finding?

  1. Move the product to the CRA's hotel room until the next visit
  2. Recommend continuing current practice because the product is unused
  3. Require the site to secure the product in a controlled-access location and document the corrective action Correct answer.
  4. Report the finding only if a participant later experiences an adverse event

Explanation

Investigational product must be stored under conditions that prevent unauthorized access and ensure accountability, so the site must secure it and document corrective action. The CRA cannot take custody of the product, and the issue warrants immediate action regardless of future events.

Question 39Clinical Research Associate Practice

Which of the following is the most appropriate way for a CRA to follow up on a corrective and preventive action plan agreed with a site?

  1. Delegate verification to the site's pharmacy technician
  2. Assume the site implemented the plan once it was signed
  3. Verify implementation during subsequent contacts and document the evidence Correct answer.
  4. Close the issue in the tracking system as soon as the plan is agreed

Explanation

A CAPA is only effective when its implementation is verified and the evidence is documented, typically during follow-up visits or contacts. Agreeing on or signing a plan does not demonstrate that the corrective action occurred.

Question 40Clinical Research Associate Practice

A CRA is reviewing a site's screening log and notices that several individuals who failed screening are not listed, although their medical records show screening assessments. What is the most appropriate interpretation?

  1. Only enrolled participants need to appear in any site log
  2. Screening logs are optional and require no reconciliation
  3. The screening log is incomplete and should be reconciled with source records Correct answer.
  4. Failed screens should be deleted from all records to protect privacy

Explanation

Screening logs must capture all individuals who underwent screening so that enrollment and screen-failure data can be reconciled with source records. Omitting failed screens undermines the integrity of enrollment reporting and cannot be justified as privacy protection.

Question 41Clinical Research Associate Practice

Which of the following best describes the CRA's responsibility when the sponsor issues a protocol amendment that affects participant procedures?

  1. Verify that the site obtains required approvals and re-consents affected participants before applying the change Correct answer.
  2. Delay all communication about the amendment until the next scheduled visit
  3. Implement the amendment at the site without waiting for IRB approval
  4. Decide independently which participants need to be re-consented

Explanation

Protocol amendments generally require IRB approval before implementation, and participants affected by changes to their participation must be re-consented as appropriate. The CRA verifies these steps occur rather than implementing changes or making consent decisions independently.

Question 42Clinical Research Associate Practice

A CRA is asked to review a site's compliance with the requirement that the investigator provide adequate medical care to participants during the trial. Which source best supports this review?

  1. The sponsor's marketing plan for the investigational product
  2. The CRA's personal notes from a previous unrelated study
  3. The site's billing invoices for routine procedures
  4. The investigator's qualifications, staffing plan, and documented arrangements for medical coverage Correct answer.

Explanation

Adequate medical care depends on the investigator's qualifications and on documented arrangements ensuring medical coverage for participants during the trial. Billing records, marketing plans, and unrelated notes do not demonstrate these arrangements.

Question 43Clinical Research Associate Practice

A CRA learns that a site's investigator has delegated informed consent discussions to a nurse who is listed on the delegation log but whose training record covers only data entry. What is the most appropriate action?

  1. Accept the practice because the nurse appears on the delegation log
  2. Instruct the nurse to sign consent forms as the investigator
  3. Report the investigator to the IRB without first discussing the finding with the site
  4. Confirm the investigator authorized the task and ensure the nurse is trained and qualified before further consent discussions Correct answer.

Explanation

Delegation requires both investigator authorization and documented training and qualifications appropriate to the task, so the nurse must be trained before continuing consent discussions. Signing as the investigator would falsify records, and escalation should follow appropriate site discussion and sponsor notification.

Question 44Clinical Research Associate Practice

Which of the following best explains why the CRA reviews the site's investigational product dispensing records against participant visit dates?

  1. To determine whether the investigator's CV is current
  2. To confirm that product was dispensed consistent with randomization assignment and visit schedule Correct answer.
  3. To verify that the IRB approval letter is on file
  4. To calculate the site's per-participant payment

Explanation

Reconciling dispensing records with visit dates and randomization confirms that participants received the correct product at the correct time, supporting accountability and protocol compliance. Payment calculations, CV currency, and IRB filings are verified through separate document reviews.

Question 45Clinical Research Associate Practice

A CRA finds that a site has been enrolling participants before the sponsor's written authorization to begin enrollment was issued. What is the most appropriate characterization of this finding?

  1. A matter solely for the site's finance department
  2. A significant finding requiring documentation, sponsor notification, and assessment of participant impact Correct answer.
  3. A minor issue that can be resolved by backdating the authorization
  4. An acceptable practice if the investigator judged enrollment urgent

Explanation

Enrollment before written sponsor authorization violates the trial's procedural safeguards and requires documentation, notification, and assessment of any impact on participants. Backdating documents or relying on investigator urgency does not legitimize the action.

Question 46Clinical Research Associate Practice

Which of the following best describes the CRA's role in verifying that a site maintains accurate and complete source documents?

  1. Deciding which source documents the site must retain
  2. Comparing source documents with CRF entries and ensuring discrepancies are resolved and documented Correct answer.
  3. Storing copies of all source documents at the sponsor's office
  4. Completing missing source entries on the site's behalf

Explanation

The CRA verifies data integrity by comparing source documents to CRF entries and ensuring discrepancies are resolved and documented. The CRA must not create source data, and retention requirements are defined by the protocol, sponsor, and regulations.

Question 47Clinical Research Associate Practice

A CRA is reviewing a site's records and finds that a participant's randomization assignment was unblinded to the site pharmacist, who then shared the assignment with the study coordinator. What is the most appropriate concern to raise?

  1. Sharing the assignment may compromise blinding and introduce bias into study conduct Correct answer.
  2. The pharmacist should have recorded the assignment in the CRF
  3. Unblinding is harmless as long as the participant is not told
  4. The coordinator should have been unblinded from the start

Explanation

Unblinding beyond the personnel who require it for safety or dispensing purposes can compromise study blinding and bias data collection. Unblinding information should be restricted, and any breach should be documented and assessed.

Question 48Clinical Research Associate Practice

What is the primary purpose of the CRA's follow-up letter after a monitoring visit?

  1. To authorize the site to continue enrollment
  2. To summarize findings, agreed actions, and responsible parties with timelines Correct answer.
  3. To replace the formal monitoring report
  4. To serve as the site's informed consent documentation

Explanation

A follow-up letter communicates findings, agreed corrective actions, responsible persons, and timelines to the site, supporting resolution of issues. It supplements but does not replace the formal monitoring report and has no role in consent or enrollment authorization.

Question 49Clinical Research Associate Practice

A CRA is reviewing a site's handling of a participant who withdrew consent. Which action by the site would be most consistent with GCP expectations?

  1. Destroying all previously collected data about the participant
  2. Enrolling the participant in a different trial immediately
  3. Clarifying the participant's preferences about further use of already collected data and documenting the withdrawal Correct answer.
  4. Continuing to collect study-specific data from the participant's records without restriction

Explanation

When a participant withdraws consent, the site should clarify what the withdrawal covers, including use of data already collected, and document the discussion. Continuing unrestricted data collection or destroying all prior data misapplies the withdrawal.

Question 50Clinical Research Associate Practice

A CRA notes that a site's monitoring visit report from three months ago documented a data query that remains unresolved with no documented follow-up. What is the most appropriate action?

  1. Delete the original finding from the monitoring report
  2. Close the query because sufficient time has passed
  3. Reopen follow-up on the query, document the delay, and escalate according to the monitoring plan Correct answer.
  4. Wait for the sponsor's next audit to address the query

Explanation

Unresolved queries require active follow-up and documentation, and persistent delays should be escalated per the monitoring plan. Time passing does not resolve a query, and altering prior reports would compromise the record.